Drew Watson

13.5k total citations · 2 hit papers
46 papers, 9.3k citations indexed

About

Drew Watson is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Drew Watson has authored 46 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 18 papers in Cancer Research and 12 papers in Molecular Biology. Recurrent topics in Drew Watson's work include Breast Cancer Treatment Studies (11 papers), Molecular Biology Techniques and Applications (10 papers) and Cancer Genomics and Diagnostics (9 papers). Drew Watson is often cited by papers focused on Breast Cancer Treatment Studies (11 papers), Molecular Biology Techniques and Applications (10 papers) and Cancer Genomics and Diagnostics (9 papers). Drew Watson collaborates with scholars based in United States, Taiwan and United Kingdom. Drew Watson's co-authors include Steven Shak, Joffre Baker, Norman Wolmark, Maureen Cronin, Soonmyung Paik, Frederick L. Baehner, Gong Tang, D. Lawrence Wickerham, Chungyeul Kim and John Bryant and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Drew Watson

44 papers receiving 9.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer

2004 4.5k citations Soonmyung Paik, Steven Shak et al. profile →
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer

2006 1.9k citations Soonmyung Paik, Gong Tang et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Drew Watson United States	20	6.2k	4.8k	3.0k	1.9k	1.6k	46	9.3k
Maureen Cronin United States	29	6.1k 1.0×	4.4k 0.9×	4.0k 1.3×	1.4k 0.8×	1.7k 1.1×	55	10.3k
Chungyeul Kim South Korea	18	4.8k 0.8×	3.7k 0.8×	2.6k 0.9×	1.3k 0.7×	1.3k 0.8×	56	7.4k
Janine Salter United Kingdom	41	4.8k 0.8×	5.1k 1.1×	2.9k 1.0×	1.2k 0.6×	2.4k 1.5×	86	8.8k
Frederick L. Baehner United States	40	8.7k 1.4×	6.9k 1.4×	4.4k 1.5×	2.5k 1.3×	2.2k 1.3×	120	14.0k
Stephen Chia Canada	47	5.9k 1.0×	7.4k 1.6×	3.2k 1.0×	1.4k 0.8×	1.4k 0.8×	234	11.5k
Lynn G. Dressler United States	27	4.8k 0.8×	5.1k 1.1×	2.7k 0.9×	1.5k 0.8×	1.3k 0.8×	51	8.6k
Maxime P. Look Netherlands	49	4.5k 0.7×	3.6k 0.8×	5.9k 2.0×	526 0.3×	1.2k 0.8×	115	10.0k
David Voduc Canada	14	4.5k 0.7×	4.5k 0.9×	3.1k 1.0×	1.0k 0.5×	857 0.5×	20	8.0k
Daniel J. Booser United States	44	3.5k 0.6×	5.2k 1.1×	2.3k 0.8×	910 0.5×	752 0.5×	105	8.1k
Semiglazov Vf Russia	46	5.6k 0.9×	8.5k 1.8×	2.1k 0.7×	1.5k 0.8×	1.2k 0.7×	239	11.9k

Countries citing papers authored by Drew Watson

Since Specialization

Citations

This map shows the geographic impact of Drew Watson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Drew Watson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Drew Watson more than expected).

Fields of papers citing papers by Drew Watson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Drew Watson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Drew Watson. The network helps show where Drew Watson may publish in the future.

Co-authorship network of co-authors of Drew Watson

This figure shows the co-authorship network connecting the top 25 collaborators of Drew Watson. A scholar is included among the top collaborators of Drew Watson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Drew Watson. Drew Watson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Packiam, Vignesh T., Ian M. McElree, Saum Ghodoussipour, et al.. (2025). Presence of an Artificial Intelligence–powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non–muscle-invasive Bladder Cancer. European Urology Oncology. 8(6). 1461–1465.

Tuteja, Sony, Xingmei Wang, Donna Capozzi, et al.. (2025). Implementation of DPYD and UGT1A1 Testing in Patients With GI Cancer: A Prospective, Nonrandomized Clinical Trial. JCO Precision Oncology. 9(9). e2500086–e2500086.

Paik, Soonmyung, Gong Tang, Steven Shak, et al.. (2023). Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer. Journal of Clinical Oncology. 41(20). 3565–3575. 5 indexed citations

Friedland, Shai, Drew Watson, Jennifer Pan, et al.. (2022). Development and Clinical Validation of a Blood Test for Early Detection of Colorectal Adenomas and Cancer for Screening and Postpolypectomy Surveillance. SHILAP Revista de lepidopterología. 1(2). 223–230. 4 indexed citations

Wen, Patrick Y., Michael Castro, Drew Watson, et al.. (2021). Superior overall survival (OS) and disease-free survival (DFS) predictions for patients with glioblastoma multiforme (GBM) using Cellworks Singula: myCare-022-03.. Journal of Clinical Oncology. 39(15_suppl). 2017–2017. 2 indexed citations

Friedland, Shai, Jennifer Pan, Drew Watson, et al.. (2021). Development and clinical validation of a blood test for early detection of colorectal adenomas and cancer.. Journal of Clinical Oncology. 39(3_suppl). 50–50. 5 indexed citations

Friedland, Shai, Jennifer Pan, Drew Watson, et al.. (2020). A sensitive and quantitative multimodal blood test for the detection of colorectal adenomas and cancer: Correlation with size and number of polyps.. Journal of Clinical Oncology. 38(15_suppl). 1555–1555. 2 indexed citations

Gulzar, Zulfiqar, et al.. (2019). Analytical validation of the CellMax platform for early detection of cancer by enumeration of rare circulating tumor cells. 8(1). 3 indexed citations

You, Jeng‐Fu, B. R. Hsieh, Heinz‐Josef Lenz, et al.. (2019). Novel Circulating Tumor Cell Assay for Detection of Colorectal Adenomas and Cancer. Clinical and Translational Gastroenterology. 10(10). e00088–e00088. 52 indexed citations

10.

Knezevic, Dejan, Audrey D. Goddard, Diana B. Cherbavaz, et al.. (2013). Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics. 14(1). 690–690. 231 indexed citations

11.

Baker, Joffre, Debjani Dutta, Drew Watson, et al.. (2011). Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. British Journal of Cancer. 104(3). 488–495. 81 indexed citations

12.

O’Connell, Michael J., Ian C. Lavery, Greg Yothers, et al.. (2010). Relationship Between Tumor Gene Expression and Recurrence in Four Independent Studies of Patients With Stage II/III Colon Cancer Treated With Surgery Alone or Surgery Plus Adjuvant Fluorouracil Plus Leucovorin. Journal of Clinical Oncology. 28(25). 3937–3944. 220 indexed citations

13.

Anderson, J. M., et al.. (2009). Molecular Characterization of Breast Cancer Core Biopsy Specimens by Gene Expression Analysis Using Standardized Quantitative RT-PCR.. Cancer Research. 69(24_Supplement). 6021–6021. 12 indexed citations

14.

Cronin, Maureen, Chithra Sangli, Mei‐Lan Liu, et al.. (2007). Analytical Validation of the Oncotype DX Genomic Diagnostic Test for Recurrence Prognosis and Therapeutic Response Prediction in Node-Negative, Estrogen Receptor–Positive Breast Cancer. Clinical Chemistry. 53(6). 1084–1091. 264 indexed citations

15.

Goldstein, Lori J., Robert M. Gray, Barrett H. Childs, et al.. (2007). Abstract Submission. Journal of Clinical Oncology. 25(18_suppl). 526–526. 2 indexed citations

16.

Paik, Soonmyung, Gong Tang, Steven Shak, et al.. (2006). Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer. Journal of Clinical Oncology. 24(23). 3726–3734. 1871 indexed citations breakdown →

17.

Mina, Lida A., Sunil Badve, Joffre Baker, et al.. (2006). Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Research and Treatment. 103(2). 197–208. 80 indexed citations

18.

Esteva, Francisco J., Ayşegül A. Şahin, Massimo Cristofanilli, et al.. (2005). Prognostic Role of a Multigene Reverse Transcriptase-PCR Assay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant Systemic Therapy. Clinical Cancer Research. 11(9). 3315–3319. 132 indexed citations

19.

Paik, Soonmyung, Steven Shak, Ge Tang, et al.. (2005). Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. Journal of Clinical Oncology. 23(16_suppl). 510–510. 73 indexed citations

20.

Gianni, Luca, Milvia Zambetti, Joffre Baker, et al.. (2005). Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer. Journal of Clinical Oncology. 23(29). 7265–7277. 457 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact